ICU Medical, Inc. (NASDAQ:ICUI) Stock Has Consensus Price Target of $192.80

ICU Medical, Inc. (NASDAQ:ICUI) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $192.80.

Several research firms recently weighed in on ICUI. Piper Sandler upped their price target on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 23rd. BTIG Research lifted their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, August 7th. KeyCorp boosted their target price on ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a report on Tuesday, July 21st. Finally, Needham & Company LLC increased their target price on ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research note on Friday, August 7th.

ICU Medical Trading Down 2.3%

Shares of NASDAQ ICUI opened at $156.03 on Monday. ICU Medical has a 1 year low of $112.50 and a 1 year high of $192.85. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. The firm has a 50-day moving average of $168.80 and a 200 day moving average of $147.95. The stock has a market cap of $3.90 billion, a P/E ratio of 132.23, a price-to-earnings-growth ratio of 2.01 and a beta of 0.86.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The business had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. During the same quarter in the prior year, the company earned $2.10 earnings per share. The business’s revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, sell-side analysts expect that ICU Medical will post 7.22 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Virginia Sanzone sold 4,856 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the sale, the vice president directly owned 14,604 shares of the company’s stock, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total transaction of $401,220.00. Following the sale, the insider owned 3,076 shares of the company’s stock, valued at approximately $548,512.32. This represents a 42.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 21,830 shares of company stock worth $3,905,003 over the last quarter. 2.10% of the stock is owned by insiders.

Institutional Investors Weigh In On ICU Medical

Several large investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in ICU Medical during the 2nd quarter valued at about $550,250,000. Jupiter Topco LLC bought a new stake in shares of ICU Medical in the second quarter worth approximately $407,786,000. Janus Henderson Group PLC grew its stake in shares of ICU Medical by 3.9% in the first quarter. Janus Henderson Group PLC now owns 2,676,012 shares of the medical instruments supplier’s stock worth $345,607,000 after acquiring an additional 99,256 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of ICU Medical by 6.8% during the first quarter. Dimensional Fund Advisors LP now owns 983,802 shares of the medical instruments supplier’s stock valued at $127,053,000 after purchasing an additional 63,026 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of ICU Medical during the fourth quarter valued at approximately $58,083,000. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and critical care. Its products support the delivery of medications, fluids, and nutrition while helping healthcare providers reduce the risk of complications associated with intravenous treatment.

The company’s product portfolio includes infusion pumps and related administration sets, needle-free connectors, vascular access devices, intravenous systems, and other products used in hospitals and alternate-care settings.